In the last trading session, 2.32 million Akebia Therapeutics Inc (NASDAQ:AKBA) shares changed hands as the company’s beta touched 0.68. With the company’s per share price at $1.95 changed hands at -$0.04 or -2.01% during last session, the market valuation stood at $425.45M. AKBA’s last price was a discount, traded about -27.18% off its 52-week high of $2.48. The share price had its 52-week low at $0.80, which suggests the last value was 58.97% up since then. When we look at Akebia Therapeutics Inc’s average trading volume, we note the 10-day average is 3.05 million shares, with the 3-month average coming to 1.84 million.

Analysts gave the Akebia Therapeutics Inc (AKBA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKBA as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Akebia Therapeutics Inc’s EPS for the current quarter is expected to be -0.05.

Akebia Therapeutics Inc (NASDAQ:AKBA) trade information

Instantly AKBA was in red as seen at the end of in last trading. With action 4.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 57.26%, with the 5-day performance at 4.84% in the green. However, in the 30-day time frame, Akebia Therapeutics Inc (NASDAQ:AKBA) is 47.73% up. Looking at the short shares, we see there were 17.68 million shares sold at short interest cover period of 14.06 days.

The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need an upside of 70.0% from its current market value. According to analyst projections, AKBA’s forecast low is 6 with 7 as the target high. To hit the forecast high, the stock’s price needs a -258.97% plunge from its current level, while the stock would need to soar -207.69% for it to hit the projected low.

Akebia Therapeutics Inc (AKBA) estimates and forecasts

Data shows that the Akebia Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 58.54% over the past 6 months, a 32.14% in annual growth rate that is considerably higher than the industry average of 17.00%. Year-over-year growth is forecast to reach -13.30% down from the last financial year.

Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 49.56M. 3 analysts are of the opinion that Akebia Therapeutics Inc’s revenue for the current quarter will be 36.08M. The company’s revenue for the corresponding quarters a year ago was 56.2M and 32.61M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -11.80%. The estimates for the next quarter sales put growth at 10.70%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.46%. The 2024 estimates are for Akebia Therapeutics Inc earnings to increase by 10.71%.

AKBA Dividends

Akebia Therapeutics Inc is expected to release its next quarterly earnings report in December.

Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 2.09% of Akebia Therapeutics Inc shares while 25.88% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 26.43%. There are 25.88% institutions holding the Akebia Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.6786% of the shares, roughly 11.64 million AKBA shares worth $11.87 million.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.526% or 9.28 million shares worth $9.46 million as of 2024-06-30.